• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Over $15M Bet On Aon? Check Out These 3 Stocks Insiders Are Buying

    2/12/24 8:36:25 AM ET
    $AON
    $CIZN
    $JSPR
    Specialty Insurers
    Finance
    Major Banks
    Finance
    Get the next $AON alert in real time by email

    Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Jasper Therapeutics

    • The Trade: Jasper Therapeutics, Inc. (NASDAQ:JSPR) 10% owner Adam Morgan acquired a total of 350,000 shares an average price of $12.95. To acquire these shares, it cost around $4.5 million.
    • What’s Happening: Jasper Therapeutics announced pricing of $50 million underwritten offering of 3.9 million shares of common stock at a price of $12.95 per share.
    • What Jasper Therapeutics Does: Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy.

    Aon

    • The Trade: Aon plc (NYSE:AON) Director Lester B Knight acquired a total of 50,000 shares at an average price of $301.97. To acquire these shares, it cost around $15.1 million.
    • What’s Happening: Aon reported weaker-than-expected fourth-quarter earnings.
    • What Aon Does: Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations.

    Don’t forget to check out our premarket coverage here

    Citizens Holding

    • The Trade: Citizens Holding Company (OTC:CIZN) Director Herbert A King bought a total of 14,000 shares at an average price of $7.89. To acquire these shares, it cost around $110,460. The company’s CEO also bought 4,951 shares of the company.
    • What’s Happening: The company said net loss for the three months ended Dec. 31, 2023 was $794, or 14 cents per share-basic.
    • What Citizens Holding Does: Citizens Holding Co is a bank holding company. Through its subsidiary, it engages in various commercial and personal banking activities, such as accepting demand deposits, savings, and time deposit accounts, making secured and unsecured loans, issuing letters of credit, originating mortgage loans, and providing personal and corporate trust services.

     

    Check This Out: Top 5 Health Care Stocks That Are Preparing To Pump In February

    Get the next $AON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AON
    $CIZN
    $JSPR

    CompanyDatePrice TargetRatingAnalyst
    Aon plc
    $AON
    2/27/2026$397.00Neutral → Outperform
    Mizuho
    Jasper Therapeutics Inc.
    $JSPR
    1/13/2026$17.00Buy
    Rodman & Renshaw
    Aon plc
    $AON
    12/16/2025$389.00Neutral
    Mizuho
    Aon plc
    $AON
    11/3/2025$402.00Neutral → Buy
    Citigroup
    Aon plc
    $AON
    9/17/2025$427.00 → $419.00Buy
    TD Cowen
    Aon plc
    $AON
    9/16/2025Peer Perform
    Wolfe Research
    Aon plc
    $AON
    9/11/2025$430.00Equal-Weight → Overweight
    Morgan Stanley
    Aon plc
    $AON
    8/13/2025$440.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AON
    $CIZN
    $JSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aon upgraded by Mizuho with a new price target

    Mizuho upgraded Aon from Neutral to Outperform and set a new price target of $397.00

    2/27/26 8:20:07 AM ET
    $AON
    Specialty Insurers
    Finance

    Rodman & Renshaw initiated coverage on Jasper Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

    1/13/26 10:20:49 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Aon with a new price target

    Mizuho initiated coverage of Aon with a rating of Neutral and set a new price target of $389.00

    12/16/25 8:46:26 AM ET
    $AON
    Specialty Insurers
    Finance

    $AON
    $CIZN
    $JSPR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.

    SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

    2/25/26 4:47:25 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Jasper Therapeutics Inc.

    SCHEDULE 13D/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    2/18/26 5:29:20 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Aon plc

    10-K - Aon plc (0000315293) (Filer)

    2/13/26 4:15:50 PM ET
    $AON
    Specialty Insurers
    Finance

    $AON
    $CIZN
    $JSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Knight Lester B bought $1,276,956 worth of Class A Ordinary Stock (4,000 units at $319.24) (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    2/12/26 4:34:45 PM ET
    $AON
    Specialty Insurers
    Finance

    Director Wiggans Thomas G bought $99,630 worth of Voting Common Stock (41,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lucas Svetlana bought $48,600 worth of Voting Common Stock (20,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:38 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AON
    $CIZN
    $JSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myriad Venture Partners Expands Executive Advisory Board as Enterprise AI Moves Into Production

    Executive Advisory Board now includes more than 30 senior leaders from Fortune 500 and global enterprisesNEW YORK, March 11, 2026 /PRNewswire/ -- Myriad Venture Partners ("Myriad"), an early-stage venture capital firm focused on defining the future of business solutions in enterprise AI, enterprise B2B software, and industrial transformation, today announced the expansion of its Executive Advisory Board, bringing the Board to more than 30 C-suite leaders from Fortune 500 and global enterprises. New executives joining the Board include leaders from GSK, Mastercard, Harley-Davidson, Meta, Oracle, and other global companies, further strengthening Myriad's hands-on model and deepening its ties t

    3/11/26 6:00:00 AM ET
    $AON
    $GSK
    $HOG
    Specialty Insurers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aon Appoints Anne Corona as CEO of North America, Elevates Lori Goltermann as Vice Chair and Appoints Farheen Dam as CEO of Enterprise Clients and Chief Client Officer

    DUBLIN, March 10, 2026 /CNW/ -- Aon plc (NYSE:AON), a leading global professional services firm, announced today that it is transitioning the North America CEO role from Lori Goltermann to Anne Corona, effective immediately, and has elevated Goltermann to serve as Vice Chair of Aon, effective March 31, 2026. With this transition, Farheen Dam has been appointed to serve as CEO of Enterprise Clients and Chief Client Officer, effective immediately. Corona, Goltermann and Dam report to Aon President and CEO Greg Case and serve on the Aon Executive Committee.As CEO of North America, Corona will build on the firm's momentum in the region delivering actionable insights, differentiated Risk Capital

    3/10/26 8:30:00 AM ET
    $AON
    Specialty Insurers
    Finance

    VIPR Announces Strategic Engagement with Aon to Transform Delegated Authority Operations

    Multi-year engagement to deliver intelligent automation and operational clarity across global reinsurance platform VIPR Solutions, a leading provider of Delegated Authority technology, has announced a multi-year engagement with Aon plc (NYSE:AON) to automate and enhance delegated authority operations across Aon's global reinsurance platform. The engagement will see Aon implement VIPR's technology suite to drive operational transparency, data accuracy, and speed to market across its delegated authority business. Through intelligent automation of bordereaux management, data analytics, and coverholder administration, VIPR technology will enable Aon to scale its operations whilst maintainin

    3/10/26 4:00:00 AM ET
    $AON
    Specialty Insurers
    Finance

    $AON
    $CIZN
    $JSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Zeidel Darren sold $1,417,784 worth of Class A Ordinary Stock (4,300 units at $329.72), decreasing direct ownership by 21% to 15,954 units (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    3/2/26 4:05:23 PM ET
    $AON
    Specialty Insurers
    Finance

    President & CEO Case Gregory C gifted 37,412 units of Class A Ordinary Stock and received a gift of 22,412 units of Class A Ordinary Stock (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    2/20/26 4:59:21 PM ET
    $AON
    Specialty Insurers
    Finance

    Chief Administrative Officer Stevens Lisa gifted 32 units of Class A Ordinary Stock, decreasing direct ownership by 0.12% to 26,321 units (SEC Form 4)

    4 - Aon plc (0000315293) (Issuer)

    2/19/26 5:02:19 PM ET
    $AON
    Specialty Insurers
    Finance

    $AON
    $CIZN
    $JSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 3:32:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Aon plc

    SC 13G - Aon plc (0000315293) (Subject)

    11/13/24 3:01:03 PM ET
    $AON
    Specialty Insurers
    Finance

    $AON
    $CIZN
    $JSPR
    Leadership Updates

    Live Leadership Updates

    View All

    Aon Appoints Anne Corona as CEO of North America, Elevates Lori Goltermann as Vice Chair and Appoints Farheen Dam as CEO of Enterprise Clients and Chief Client Officer

    DUBLIN, March 10, 2026 /CNW/ -- Aon plc (NYSE:AON), a leading global professional services firm, announced today that it is transitioning the North America CEO role from Lori Goltermann to Anne Corona, effective immediately, and has elevated Goltermann to serve as Vice Chair of Aon, effective March 31, 2026. With this transition, Farheen Dam has been appointed to serve as CEO of Enterprise Clients and Chief Client Officer, effective immediately. Corona, Goltermann and Dam report to Aon President and CEO Greg Case and serve on the Aon Executive Committee.As CEO of North America, Corona will build on the firm's momentum in the region delivering actionable insights, differentiated Risk Capital

    3/10/26 8:30:00 AM ET
    $AON
    Specialty Insurers
    Finance

    Aon Joins Ferrari Hypersail as Premium Partner

    Aon Expands Ferrari Partnership into High-Performance Sailing, Promoting Innovation and ResilienceMILAN, Feb. 17, 2026 /CNW/ -- Aon plc (NYSE:AON), a leading global professional services firm, today announced that it will serve as the Premium Partner of Ferrari Hypersail, an unprecedented marine initiative dedicated to high-performance sailing.In 2025, Aon became an Official Partner of the Scuderia Ferrari HP Formula One team through a multi-year agreement. By extending their relationship from the racetrack to the water, Aon aims to demonstrate how resilience and better decision-making can unlock new possibilities for clients and set new standards in competitive sport. This partnership will

    2/17/26 9:00:00 AM ET
    $AON
    Specialty Insurers
    Finance

    Aon Appoints Joe Peiser as CEO of Risk Capital

    DUBLIN, Feb. 12, 2026 /PRNewswire/ -- Aon plc (NYSE:AON), a leading global professional services firm, today announced the appointment of Joe Peiser as CEO of Risk Capital.  In this role, Peiser will lead Aon's Risk Capital capabilities across Commercial Risk and Reinsurance Solutions. Peiser will continue to report to Andy Marcell, CEO of Global Solutions for Aon. A search for the role of CEO of Commercial Risk is underway. Peiser's appointment reflects Aon's broader strategy to strengthen how the firm helps clients navigate increasing volatility by connecting risk with the most efficient forms of capital. Peiser's enhanced leadership role will accelerate Aon's work to deliver solutions tha

    2/12/26 8:00:00 AM ET
    $AON
    Specialty Insurers
    Finance

    $AON
    $CIZN
    $JSPR
    Financials

    Live finance-specific insights

    View All

    Citizens Holding Company Reports Earnings

    Citizens Holding Company (the "Company") (OTCQX:CIZN) announced today results of operations for the three and twelve months ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202603389/en/ (in thousands, except share and per share data) Net income for the three months ended December 31, 2025 was $2,079 or $0.37 per share-basic and diluted, a linked-quarter decrease of $278, or 11.8%, from net income of $2,357, or $0.42 per share-basic and diluted, for the three months ended September 30, 2025. Net income increased $762, or 57.8%, from net income of $1,317, or $0.23, per share-basic and diluted for the s

    2/2/26 9:00:00 AM ET
    $CIZN
    Major Banks
    Finance

    Aon Reports Fourth-Quarter and Full-Year 2025 Results

    DUBLIN, Jan. 30, 2026 /PRNewswire/ -- Aon plc (NYSE:AON) today reported results for the three and twelve months ended December 31, 2025. Aon delivered another quarter of strong performance and finished 2025 with 9% total revenue growth, 6% organic revenue growth and double-digit free cash flow growth, demonstrating the durability and consistency of our growth modelWe paid down $1.9 billion in debt in 2025 and successfully met our leverage objective in the fourth quarter. We expect our strong balance sheet position will enable us to execute our disciplined capital allocation model in 2026, balancing investment in high-return M&A and capital return to shareholdersWe are introducing 2026 guida

    1/30/26 6:30:00 AM ET
    $AON
    Specialty Insurers
    Finance

    Aon Global Limited Announces Redemption in Full and Delisting of 2.875% Senior Notes due 2026 from the New York Stock Exchange

    LONDON, Jan. 15, 2026 /PRNewswire/ -- Aon Global Limited (f/k/a Aon plc) (the "Company"), a wholly owned subsidiary of Aon plc (NYSE:AON) ("Aon") today announced that it intends to redeem in full and delist its 2.875% Senior Notes due 2026 (the "Notes") from the New York Stock Exchange (NYSE) and to withdraw the registration of the Notes under Section 12(b) of the Securities Exchange Act of 1934, as amended. The Company is undertaking these actions in connection with the full redemption of the Notes in accordance with the Indenture, dated May 24, 2013, as amended and restated on April 1, 2020, among the Company, Aon Corporation, Aon plc, Aon Global Holdings plc, and The Bank of New York Mel

    1/15/26 4:05:00 AM ET
    $AON
    Specialty Insurers
    Finance